Skip to main content
. 2011 Jul 15;22(14):2423–2435. doi: 10.1091/mbc.E11-04-0306

FIGURE 1:

FIGURE 1:

Down-regulated E-cad expression is required for 3D outgrowth of breast cancer cells. (A) NM-E cells were treated with TGF-β1 (5 ng/ml) for 48 h (Post-EMT) before their 3D culture for an additional 4 d in the absence (NS) or presence of EGF (50 ng/ml) as indicated; 3D outgrowth was monitored by a bioluminescence growth assay. Inset, Immunoblot verifying down-regulation of E-cad in NM-E cells upon TGF-β1induced EMT. Data are the mean (±SE) of three independent experiments completed in triplicate. *, **, p < 0.05. (B) 3D outgrowth of human MDA-MB-231 breast cancer cells (231) expressing E-cad or GFP as a control was monitored longitudinally by bioluminescence. Data are the mean (±SE) of three independent experiments completed in triplicate. Inset, Immunoblot analysis verifying recombinant E-cad expression. (C) 3D outgrowth of murine 4T1 breast cancer cells was monitored by bioluminescence. Data are the mean (±SE) of three independent experiments completed in triplicate. Inset, E-cad protein levels were monitored by immunoblot analyses 5 d after propagating the cells in 2D or 3D cultures. (D) 4T1 cells engineered to stably express an E-cadluciferase reporter construct were grown in the absence or presence of TGF-β1 (5 ng/ml) under 2D or 3D conditions as in (C). Data are the mean (±SE) E-cadfirefly luciferase/CMVrenilla luciferase ratios obtained from three independent experiments completed in triplicate.